Q-omics provides the consensus-scored STAR profile across patient tissues and cancer cell-line models. STAR expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAR is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, STAR RNA expression shows 14,189 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUSC, and ESCA as cancer lineages where STAR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAR survival associations across molecular data types. STAR RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAR RNA expression–survival associations across cancer types. High STAR expression shows unfavorable associations in KIRC, but favorable associations in HNSC, UVM, LUAD, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAR RNA expression.
This table summarizes STAR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for STAR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAR shows lower tumor expression in COAD, BRCA, THCA and PRAD and higher tumor expression in LUSC and HNSC. The LUSC box plot shows higher STAR RNA expression in tumor versus normal tissue (log2 FC = +1.494, t-test p < 0.001).
This table shows molecular features associated with STAR in patient tissues and cancer cell lines. In patient samples, STAR shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, STAR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
